Financial Performance - Total revenue for Q1 2024 reached RMB 576,333,115.25, an increase of 26.4% compared to RMB 455,779,558.55 in Q1 2023[9] - The company's net profit for Q1 2024 reached ¥50,597,085.17, a significant increase from ¥22,037,147.18 in Q1 2023, representing a growth of approximately 130%[14] - Operating profit for the period was ¥66,663,340.33, compared to ¥28,440,895.40 in the same quarter last year, indicating an increase of about 134%[14] - Total revenue from sales of goods and services amounted to ¥694,754,702.08, up from ¥508,576,253.98 in Q1 2023, reflecting a growth of approximately 36.6%[17] - The total comprehensive income attributable to the parent company was ¥49,223,278.93, compared to ¥20,987,154.16 in Q1 2023, reflecting an increase of about 134%[15] - The net profit attributable to shareholders of the listed company was ¥49,223,278.93, a significant increase of 134.54% compared to the same period last year[44] Operating Costs and Expenses - Total operating costs for Q1 2024 were RMB 509,910,800.22, up from RMB 427,154,766.87 in Q1 2023, reflecting a 19.4% increase[9] - Research and development expenses increased to ¥5,831,085.27 from ¥3,183,767.55, showing a growth of approximately 83%[14] - The company’s financial expenses improved, with interest expenses recorded at ¥3,989,218.52, down from ¥144,000.00 in the previous year[14] Assets and Liabilities - The company's total assets amounted to RMB 2,650,434,736.29, compared to RMB 2,435,684,057.33 in the previous period, indicating a growth of 8.8%[4] - Total liabilities increased to RMB 1,271,542,815.53 from RMB 1,107,389,422.48, representing a rise of 14.8%[6] - Cash and cash equivalents at the end of the period totaled ¥798,763,621.12, up from ¥608,483,017.48 at the end of Q1 2023, indicating a growth of approximately 31.2%[22] - The equity attributable to shareholders of the listed company was ¥1,587,695,586.51, up 3.20% from the previous year-end[46] Cash Flow - The total cash flow from operating activities was ¥174,927,725.12, a substantial rise from ¥21,583,761.97 in the previous year[21] - The net cash flow from operating activities was ¥174,927,725.12, showing a remarkable increase of 710.46% year-on-year[44] - The company’s investment activities resulted in a net cash outflow of ¥198,159,457.69, compared to a smaller outflow of ¥7,959,268.53 in the previous year[21] Shareholder Information - The number of circulating shares held by the top shareholder, Wuhu Lian Tai Investment Management Center, is 180,509,529 shares[8] - The number of common shareholders at the end of the reporting period was 125,526[36] - The company has not reported any changes in the top 10 shareholders' participation in margin trading and securities lending[2] Earnings Per Share - The company reported a basic earnings per share of ¥0.0274 for Q1 2024, compared to ¥0.0117 in Q1 2023, marking an increase of 134%[15] - Basic earnings per share for Q1 2024 were ¥0.0274, reflecting a 134.19% increase compared to the previous year[44] Other Financial Information - The company has not identified any non-recurring gains or losses that are significant for this quarter[47] - Other non-operating income and expenses amounted to 792,644.12[54] - The income tax impact was 221,660.41[54] - The total non-recurring gains and losses after tax amounted to 570,983.72[54] - The company is not applying new accounting standards for the first time in 2024[3] - The weighted average return on equity for the quarter was 3.15%, an increase of 1.87 percentage points year-on-year[44] - The company reported a significant increase in sales scale and net profit margin during the reporting period[47] - Inventory decreased to RMB 89,939,743.57 from RMB 139,145,493.78, showing a reduction of 35.5%[4] - The company’s cash and cash equivalents increased to RMB 71,168,745.03 from RMB 59,529,147.22, a growth of 19.5%[4] - The company reported accounts receivable of RMB 111,927,013.70, an increase from RMB 103,455,360.81 in the previous period[4]

证券代码：600186 证券简称：莲花健康 公告编号：2024—032 莲花健康产业集团股份有限公司 2023年年度经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上海证券交易所上市公司自律监管指引第 3 号——行业信息披露》之 《第十四号——食品制造》第十四条相关规定，现将莲花健康产业集团股份有限 公司 2023 年年度主要经营数据公告如下： 一、2023 年年度主要经营数据 1、主营业务按照产品类别分类情况 | | | 单位：元 | | 币种：人民币 | | --- | --- | --- | --- | --- | | 产品收入 | 2023 年度 | 2022 | 年度 | 同比变动（%） | | 味精等氨基酸调味品 | 1,622,886,906.85 | 1,284,161,250.53 | | 26.38 | | 鸡精等复合调味品 | 256,831,053.27 | 189,420,139.78 | | 35.59 | | 算力服务 | 764,601.77 | | | | | 面粉和面制 ...

Financial Performance - The company achieved a revenue of 2.101 billion RMB, representing a year-on-year growth of 24.23%[7] - The net profit attributable to shareholders reached 129.93 million RMB, a significant increase of 181.26% compared to the previous year[1] - The total operating revenue for 2023 reached ¥2,100,722,964.05, an increase of 24.2% compared to ¥1,691,055,172.21 in 2022[17] - The net profit for 2023 was ¥130,679,857.81, compared to ¥47,004,167.57 in 2022, reflecting a significant increase[19] - The gross profit margin for the company improved to 17.7% in 2023, up from 15.8% in 2022[17] - The company achieved sales revenue of CNY 1,766,437,437.51 in 2023, up from CNY 1,397,084,755.33 in 2022, marking a growth of approximately 26.4%[39] - The net profit for 2023 was ¥116,731,311.91, which is a significant increase of 97.8% from ¥58,837,946.63 in 2022[26] - The total comprehensive income attributable to the parent company was ¥129,936,459.38, up from ¥46,210,872.10 in the previous year[22] Sales and Market Performance - The company sold 158,600 tons of monosodium glutamate, 26,300 tons of chicken essence, and 26,400 tons of flour during the reporting period[1] - Online sales generated ¥76,295,241.01, a staggering increase of 317.32% year-over-year[17] - The revenue from the North China region was ¥154,845,459.61, marking a 26.17% increase compared to the previous year[17] - The company reported a significant increase in the revenue from the South China region, which was ¥328,019,156.25, but showed a decline of 18.30% year-over-year[17] - The company's main business revenue for the reporting period reached CNY 2,098,649,155.63, with a gross profit margin of 18.54% for amino acid seasonings[158] - The company maintains a leading position in the domestic retail market for MSG, with its "Lianhua" brand recognized nationally[169] Research and Development - The company’s R&D expenses increased by 33.29% to 28.73 million RMB, reflecting its commitment to innovation[7] - The company is actively pursuing a dual-driven strategy to develop a second growth curve in the smart computing field[1] - The company plans to enhance its merger and acquisition efforts, focusing on the condiment and food industry, to capitalize on domestic market opportunities[170] - The company aims to leverage its national-level research and testing centers to enhance product development and innovation[170] Digital Transformation and Technology - The company accelerated its digital transformation, utilizing big data, cloud computing, and artificial intelligence to enhance operational efficiency and market competitiveness[1] - The company established a wholly-owned subsidiary, Lianhua Technology, to explore the smart computing sector and has initiated strategic partnerships with industry leaders[1] - The company intends to strengthen its capabilities in intelligent computing and technology innovation, aligning with national strategic directions[170] - The company is committed to building intelligent computing centers in key domestic nodes to support the rapid development of the artificial intelligence industry[170] Financial Management and Cash Flow - The company’s cash flow from operating activities was 74.02 million RMB, up 34.66% year-on-year[7] - The total cash inflow from operating activities was ¥2,454,723,838.99, compared to ¥1,929,757,454.37 in 2022, showing strong operational performance[29] - The company reported a net cash outflow from investing activities of CNY 126,037,932.00, compared to CNY 46,053,004.28 in the previous year[39] - The total cash outflow from operating activities was CNY 1,726,932,897.63, resulting in a net cash flow from operating activities of CNY 50,471,447.38[39] Corporate Governance and Compliance - The company held 6 shareholder meetings during the reporting period, ensuring all shareholders could fully exercise their rights[196] - The board of directors convened 14 times, adhering to the company's articles of association and decision-making rules[196] - The supervisory board met 11 times, ensuring compliance with legal and regulatory requirements[196] - The company continues to enhance its internal control mechanisms and governance levels in accordance with relevant laws and regulations[199] Strategic Planning and Future Outlook - The company plans to expand its market presence and invest in new technologies to drive future growth[25] - The company aims to achieve approximately CNY 3.3 billion in revenue and CNY 350 million in operating profit for 2024[170] - The company is targeting a new growth curve while maintaining its core business focus for the upcoming year[193] - The company emphasizes the importance of risk awareness regarding future plans and development strategies[91]

公司于近日接到控股股东莲泰投资通知，获悉其所持有本公司的部分股份被 质押，具体事项如下： 证券代码：600186 证券简称：莲花健康 公告编号：2024-027 莲花健康产业集团股份有限公司 关于控股股东股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 莲花健康产业集团股份有限公司（以下简称"公司"或"莲花健康"）控股 股东芜湖市莲泰投资管理中心（有限合伙）（以下简称"莲泰投资"）持有公司 股份数量为 180,509,529 股，占公司总股本比例为 10.06%；累计质押数量（含 本次）143,510,000 股，占其持股数量比例为 79.50%。 一、上市公司股份质押 | 股东 | 是否为 | 本次质押股 | 是否 | 是否 | 质押 | 质押 | | 占其所 | 占公司 | 质押 融资 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 控股股 | | 为限 | 补充 | 起始 | 到期 | 质权人 ...

报 当前股价（元） 3.86 52 周价格范围（元） 2.69-7.89 2024 年 04 月 17 日 基本数据 2024-04-16 总股本（百万股） 1794 日均成交额（百万元） 458.56 司 究 —莲花健康（600186.SH）公司事件点评报告 投资要点 根据 2023 年业绩快报，2023 年公司实现总营收 21.01 亿元 （+24%），公司在品牌复兴战略指引下加强市场推广动作， 同时股权激励计划进一步释放发展活力，主营业务规模持续 扩张。归母净利润 1.28 亿元（+176%），扣非净利润 1.15 亿 元（+85%），由于公司原材料成本下降，同时不断优化物流 费用/提高运营效率，盈利能力显著提升。根据 2024 年第一 季度业绩预告，2024Q1 公司预计实现归母净利润 0.45-0.50 亿元（+114%-138%），扣非归母净利润 0.44-0.49 亿元 （+110%-134%），降本增效成效持续释放。 公司管理层以董事会制定的"品牌复兴战略"为指引，以市 场为导向，持续优化营销网络布局、加强市场推广及销售工 作，销售收入实现较快增长。产品上，公司推进味精主业渠 道下沉，深挖存量 ...

二、审议通过《关于聘任公司董事会秘书的议案》 具体详见公司于同日在指定信息披露媒体披露的《关于高管辞职暨聘任高 管、董事会秘书并调整审计委员会委员的公告》（公告编号：2024-026）。 证券代码：600186 证券简称：莲花健康 公告编号：2024—025 莲花健康产业集团股份有限公司 第九届董事会第十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 莲花健康产业集团股份有限公司（以下简称"公司"）第九届董事会第十五 次会议通知于 2024 年 4 月 12 日发出，于 2024 年 4 月 16 日以现场和通讯相结合 的方式召开。本次会议应出席董事 10 人，实际出席董事 10 人。会议由董事长李 厚文先生主持，现场会议在公司会议室召开，会议的召开符合《公司法》及《公 司章程》的有关规定。会议审议并表决通过了以下议案： 一、审议通过《关于聘任公司高级管理人员的议案》 具体详见公司于同日在指定信息披露媒体披露的《关于高管辞职暨聘任高 管、董事会秘书并调整审计委员会委员的公告》（公告编号：2024-026）。 ...

证券代码：600186 证券简称：莲花健康 公告编号：2024—026 截至本公告披露日，梅申林先生作为公司 2023 年股票期权与限制性股票激 励计划的激励对象，直接持有公司已获授但未行权的股票期权 300,000 份和未解 除限售的股票合计 300,000 股。陆金鑫先生未持有公司股份。 二、聘任高级管理人员、董事会秘书的情况 2024 年 4 月 16 日，公司召开了第九届董事会第十五次会议，审议通过了 《关于聘任公司高级管理人员的议案》《关于聘任公司董事会秘书的议案》，同 意聘任曾彦硕先生为公司高级副总裁、梅申林先生为公司首席运营官、陆金鑫先 生为公司董事会秘书（简历详见附件）。任期自董事会审议通过之日起至第九届 董事会任期届满为止。 三、调整审计委员会委员的情况 莲花健康产业集团股份有限公司 关于高管辞职暨聘任高管、董事会秘书并调整审计 委员会委员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 莲花健康产业集团股份有限公司（以下简称"公司"）于 2024 年 4 月 16 日 召开了第九届董事会第十五次会议， ...

（一）变更原因和日期 证券代码：600186 证券简称：莲花健康 公告编号：2024—023 莲花健康产业集团股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 莲花健康产业集团股份有限公司（以下简称"公司"）根据中华人民共 和国财政部（以下简称"财政部"）颁布的《企业会计准则解释第 17 号》变更 相应的会计政策，本次会计政策变更事项属于按照法律法规或者国家统一的会计 制度要求的会计政策变更，无需提交公司董事会、股东大会审议。本次会计政策 变更不涉及对以前年度损益的追溯调整，不会对公司财务状况、经营成果和现金 流量产生重大影响。 一、会计政策变更情况概述 二、本次会计政策变更对公司的影响 本次会计政策变更是公司根据财政部颁布的《准则解释第 17 号》的相关规 定和要求进行的合理变更，变更后的会计政策能够更加客观、公允地反映公司的 财务状况和经营成果，符合相关法律法规的规定和公司的实际情况。本次会计政 策变更不涉及对以前年度损益的追溯调整，不会对公司的财务状况、经营成果和 现金 ...

证券代码：600186 证券简称：莲花健康 公告编号：2024—024 莲花健康产业集团股份有限公司 关于董事辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 莲花健康产业集团股份有限公司（以下简称"公司"）董事会近期收到邓同 森先生的书面辞职报告。因个人原因，邓同森先生申请辞去公司董事及董事会审 计委员会委员、董事会提名委员会委员职务，辞职后邓同森先生不再担任公司任 何职务。 根据《公司法》、《公司章程》及有关法律、法规的规定，邓同森先生辞去 董事职务不会导致公司董事会人数低于法定最低人数，不会影响公司董事会正常 运作，亦不会影响公司的正常生产和经营。邓同森先生的辞职报告自送达董事会 之日起生效。公司将按照法定程序尽快补选董事和董事会审计委员会委员。 邓同森先生在任职期间，始终恪尽职守、勤勉尽责，为促进公司规范运作和 健康发展发挥了重要作用，公司及公司董事会对其在任职期间所做出的贡献表示 衷心感谢！ 特此公告。 莲花健康产业集团股份有限公司董事会 2024 年 4 月 9 日 1 截至本公告披露日，邓同森先生作为公 ...

北京市金杜律师事务所 关于莲花健康产业集团股份有限公司 2024 年第二次临时股东大会 之法律意见书 致：莲花健康产业集团股份有限公司 北京市金杜律师事务所（以下简称本所）接受莲花健康产业集团股份有限公司 （以下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证券法》）、 《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理委员会《上 市公司股东大会规则（2022 年修订）》（以下简称《股东大会规则》）等中华人民 共和国境内（以下简称中国境内，为本法律意见书之目的，不包括中国香港特别行 政区、中国澳门特别行政区和中国台湾地区）现行有效的法律、行政法规、规章及 规范性文件和现行有效的《莲花健康产业集团股份有限公司章程》（以下简称《公 司章程》），指派律师出席了公司于 2024 年 4 月 1 日召开的 2024 年第二次临时股 东大会（以下简称本次股东大会），并就本次股东大会相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1. 经公司 2023 年第五次临时股东大会审议通过的《莲花健康产业集团股份 有限公司章程》； 6. 出席现场会议的股东的 ...